Posts Archive

NCT04352205: Phase 2: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure NCT04352205:...

OPTIMAL-HiChemo NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma...

Publication Newly Diagnosed Multiple Myeloma Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5...

NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission NCT04221178: Stopping Maintenance...

NCT04430894: Phase 2: KRDI in Transplant-Eligible MM KRDI in Transplant-Eligible MM This research study is testing the efficacy of an...

(IsKia TRIAL) (IsKia) - (EMN24/HOVON503) NCT04483739: Phase 3: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for...

Official Title: A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and...

KarMMa-4 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) Relapsed...

NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed...

NCT04096066: Phase 3: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant (KRd vs Rd)...

AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...

DRAMMATIC SWOG S1803 NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct...

NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM...

EMN 18 Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib...

DREAMM 9 - Transplant Ineligible - Newly Diagnosed Multiple Myeloma Part 1: Dose escalation and cohort expansion Part 2: Dose selection...

CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...

Dara-KRd NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed...

IFM2017_03 NCT03993912: Phase 3 - Lenalidomide and SC Daratumumab vs Lenalidomide and Dexamethasone in NDMM(IFM2017_03) This is a Phase...

NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed...